← Human Trials & Peer-Reviewed Studies
Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity.
Plain-language guide to PMID 17785361 (2007): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 17785361
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Pasarica M et al. (5 authors)
- DOI
- 10.1210/jc.2007-0786
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Their objective was to determine the effects of supraphysiological GH therapy on the metabolic syndrome and visceral adiposity in men with low blood levels of IGF-I and the durability of these effects after stopping GH therapy.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, men only.
Thirty nondiabetic middle-aged men with central adiposity (body mass index > 27 kg/m(2); waist circumference > 102 cm) participated.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
What Was Measured
The subject headings attached to it are Absorptiometry, Photon, Adipose Tissue, Adiposity, Blood Pressure, Body Composition, Energy Metabolism and Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.